Henry Schein (HSIC) Q2 EPS Drops 11%

Henry Schein (NASDAQ:HSIC), a healthcare solutions company focused on distributing dental and medical products, released its quarterly results on August 5, 2025. The quarter’s most notable development was a drop in profitability, as both GAAP diluted EPS ($0.70) and non-GAAP diluted EPS ($1.10) declined compared to the prior-year period, with Non-GAAP earnings per share (EPS) of $1.10 came in well below analyst expectations of $1.19 and declining 10.6% from $1.23 in the prior-year period. Total revenue (GAAP) reached $3.24 billion, and showing 3.3% as-reported sales growth from the year-ago result. Despite revenue growth, heightened expenses, shrinking margins—especially in U.S. dental distribution—and larger restructuring charges led to lower GAAP net income. The quarter reflected continued strength in the specialty and technology solutions businesses but marked ongoing pressure and underperformance against both internal goals and market estimates, as evidenced by non-GAAP EPS of $1.10, which missed the analysts' estimate of $1.19 by approximately 7.6%. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Henry Schein (NASDAQ:HSIC) operates as a global distributor of healthcare products and services, serving more than one million customers across dental and medical practices, laboratories, and alternate care settings. It delivers a wide selection of consumables, equipment, pharmaceuticals, and services, supported by a network of 36 distribution centers and operations in 33 countries. The company also offers technology platforms for healthcare providers, including practice management software and cloud-based solutions.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool